AI
TGTX icon

Atria Investments’s TG Therapeutics TGTX Stock Holding History

Atria Investments’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$740K Buy
13,464
+1,141
+9% +$46.7K 0.01% 1285
2026
Q1 		$409K Buy
12,323
+5,026
+69% +$150K ﹤0.01% 1556
2025
Q4 		$218K Buy
+7,297
New +$238K ﹤0.01% 1924

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Atria Investments's TGTX Position: Q2 2026 in Review

Atria Investments increased its TG Therapeutics (TGTX) stake by 9.3% in Q2 2026, buying an estimated $46.7K and bringing the position to 13,464 shares worth $740K. The position accounts for 0.01% of the portfolio, ranked #1285.

Atria Investments first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Atria Investments held 13,464 shares of TG Therapeutics worth $740K as of Q2 2026.
  • Atria Investments bought 1,141 TG Therapeutics shares in Q2 2026, an estimated $46.7K.
  • TG Therapeutics made up 0.01% of Atria Investments's portfolio in Q2 2026, its #1285 holding.
  • Atria Investments first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.